Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORG-ZYME is a digestive enzyme supplement developed and marketed by Allgems Healthcare. Positioned within the company's gastrointestinal (GI) portfolio as a branded generic, it is indicated for the management of digestive enzyme insufficiency and as a general digestive aid. The product is designed to assist in the breakdown of complex dietary components, such as carbohydrates and proteins, thereby alleviating symptoms of dyspepsia, bloating, and indigestion. While specific ingredients are not explicitly listed on the company's pipeline, such formulations in the Indian market typically contain a combination of amylolytic enzymes (like fungal diastase) and proteolytic enzymes (like pepsin). It is administered orally and is currently in the approved/marketing phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ORG-ZYME.